Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
- Conditions
- Interventions
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 256
- Registration Number
- NCT00888329
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT00871910
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- S. Maria Hospital, Terni
- Target Recruit Count
- 580
- Registration Number
- NCT00869973
- Locations
- 🇮🇹
Fausto Roila, Terni, Italy
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Main Line Health
- Target Recruit Count
- 50
- Registration Number
- NCT00835965
- Locations
- 🇺🇸
Lankenau Hospital, Wynnewood, Pennsylvania, United States
A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
- Conditions
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT00819039
- Locations
- 🇲🇽
MSD, Mexico City, Mexico
🇹🇷Merck Sharp & Dohme Ilaclari Ltd. Sti, Istanbul, Turkey
🇪🇸Merck Sharp and Dohme de Espana S.A., Madrid, Spain
A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Duke University
- Target Recruit Count
- 73
- Registration Number
- NCT00736073
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers
- Conditions
- Interventions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2008-08-01
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00726960
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00719173
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Drexel University
- Target Recruit Count
- 115
- Registration Number
- NCT00717054
- Locations
- 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Drexel University College of Medicine
- Target Recruit Count
- 115
- Registration Number
- NCT00659737
- Locations
- 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.